Unknown's questions to Teleflex Inc (TFX) leadership • Q2 2025
Question
An analyst from Piper Sandler, on behalf of Matt O'Brien, asked for more details on the progress of the NewCo separation or sale and whether the company was leaning toward one option. They also sought confirmation on whether UroLift is still expected to return to growth next year given the proposed CMS rule changes.
Answer
CEO Liam Kelly stated that the company is pursuing parallel paths (sale and spin) with the 'North Star' of maximizing shareholder value, noting significant progress with preliminary buyer meetings. Regarding UroLift, he called the proposed 10% reimbursement uplift 'incredibly encouraging' and confirmed it would 'definitely be a help and not a hindrance' to the product's return to growth in 2026.